How does PTP's PB Ratio compare to its peers?

Insufficient data to calculate PTP's Price-To-Book Ratio vs. peers for valuation analysis.

How does PTP's PB Ratio compare vs other companies in the DE Medical Equipment Industry?

Insufficient data to calculate PTP's Price-To-Book Ratio vs. industry for valuation analysis.

What is PTP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate PTP's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of PTP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate PTP's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

PTP Stock Overview

Operates as a clinical-stage radiopharmaceutical development company. More details

PTP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Volatile share price over the past 3 months compared to the German market

Does not have a meaningful market cap (€72M)

My Notes

Capture your thoughts, links and company narrative

Pentixapharm Holding AG Competitors

Paul Hartmann

DB:PHH2

€795.6m

PULSION Medical Systems

MUN:PUS

€133.6m

VITA 34

XTRA:V3V

€70.1m

LIMES Schlosskliniken

XTRA:LIK

€93.2m

Price History & Performance

Summary of share price highs, lows and changes for Pentixapharm Holding
Historical stock prices
Current Share Price	€2.92
52 Week High	€5.10
52 Week Low	€2.81
Beta	0
1 Month Change	1.04%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-35.11%

Recent updates

Shareholder Returns

	PTP	DE Medical Equipment	DE Market
7D	-2.5%	-3.0%	-2.6%
1Y	n/a	-7.8%	7.1%

Return vs Industry: Insufficient data to determine how PTP performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how PTP performed against the German Market.

Price Volatility

Is PTP's price volatile compared to industry and market?
PTP volatility
PTP Average Weekly Movement	8.5%
Medical Equipment Industry Average Movement	6.7%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: PTP's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine PTP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2019	n/a	Andreas Eckert	www.pentixapharm.com

Pentixapharm Holding AG operates as a clinical-stage radiopharmaceutical development company. It focuses on developing CXCR4 ligand-based radiopharmaceutical approaches for diagnostic and therapeutic programs in various hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. The company’s clinical pipeline includes PentixaTher, an Yttrium-90-based therapeutic against non-Hodgkin lymphomas; and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Fundamentals Summary

How do Pentixapharm Holding's earnings and revenue compare to its market cap?
PTP fundamental statistics
Market cap	€72.40m
Earnings (TTM)	€0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is PTP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PTP income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€0
Earnings	€0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did PTP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 09:20
End of Day Share Price	2024/12/19 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pentixapharm Holding AG is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Pentixapharm Holding DB:PTP Stock Report